Should angiotensin receptor blockers be regarded as first-line drugs for stroke prevention in both primary and secondary prevention Settings?

Benefit-risk profile of lipid-lowering medicines continues to be positive, but first-line treatment is not recommended.

Given the similarly equivocal evidence of efficacy for epinephrine, either drug could be considered the first-line agent in cardiac arrest.